Navigation Links
Final OPAL Phase II Results of Tosedostat Demonstrate Significant Response Rates in Elderly Patients with Treatment Refractory or Relapsed Primary or Secondary Acute Myeloid Leukemia (AML)
Date:12/13/2011

SAN DIEGO, Dec. 13, 2011 /PRNewswire/ -- Cell Therapeutics, Inc. ("CTI") (NASDAQ: CTIC and MTA: CTIC) and Chroma Therapeutics Ltd. announced that final results from the phase II OPAL study of tosedostat in elderly patients with relapsed or refractory acute myeloid leukemia (AML) were presented by Jorge Cortes, M.D. of the University of Texas M.D. Anderson Cancer Center during the Acute Myeloid Leukemia - Therapy, excluding Transplantation: Clinical Studies session at the American Society of Hematology Annual Meeting.  Tosedostat is a novel, orally administered amino acid deprivation response (AADR) inducer, which targets and deprives sensitive tumor cells of the amino acid building blocks they need to make proteins necessary for tumor cell survival.

 

Highlights of the study:

 

  •  Elderly (median age 72 years) poor risk patient group,  approximately half (52%) of whom had AML refractory to their last treatment prior to starting tosedostat
  • Fifty-one  percent (51%) of patients experienced disease control with 22% achieving a major leukemic response: 12% of patients achieved a complete (CR) bone marrow responses
  • While responses were observed across all types of prior AML therapy, 36% of patients who had failed treatment with hypo-methylating agents (HMAs) achieved a response, similarly 37% of patients with secondary AML from prior myelodysplastic syndrome (MDS) achieved a response, suggesting this population is potentially highly sensitive to tosedostat anti-leukemic activity
  • Median overall survival for patients achieving a CR was 323 days, Partial Response (PR) 195 days, Stable Disease (SD) 162 days
  •  Tosedostat was well tolerated with most frequent grade >3 side effect being diarrhea (4%), fatigue (21%), and febrile neutropenia (29%)
  • '/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. VolitionRX Limited Issues 525,000 Shares to ValiRx; Final Requirement of Share Purchase Agreement
2. Tosedostat OPAL Study Final Results Selected for Oral Presentation at the 2011 American Society of Hematology (ASH) Annual Meeting
3. TechAmerica and the Technology Association of Georgia Name Dr. Jay Yadav, CardioMEMS Founder & CEO as a Spirit of Endeavor Award Finalist
4. Natures Bioceuticals Finalizes Agreement for the Purchase of Proprietary Weight Loss Formula
5. Natures Bioceuticals Finalizes The Purchase of Cold and Flu Formula
6. Actress Christina Hendricks Urges Women to Join Her in the Final Weeks of the LATISSE® Wishes Challenge to Increase Money Raised for the Make-A-Wish Foundation® from $390,000 to Campaign Goal of $500,000
7. Tibotec to Present Final Safety and Efficacy Results From Phase 2b PILLAR Study of Once-Daily TMC435 in Late-Breaker at AASLD
8. Finalists of the 2011 CPhI Innovation Awards Announced
9. Cantel Medicals Minntech Subsidiary Named Finalist for 2011 Tekne Awards
10. Lupin Receives Final Approval to Market Generic Ultram® ER
11. Perrigo Announces FDA Final Approval for Ketoconazole Foam, 2%
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... , July 30, 2015 Edwards Lifesciences Corporation ... of heart valves and hemodynamic monitoring, today announced that ... of Directors. "Bob is an ardent champion for ... true privilege to have him on Edwards, board as we ... , Edwards, chairman and CEO.  "Bob has provided a valuable ...
(Date:7/30/2015)...  Tandem Diabetes Care®, Inc. (NASDAQ: TNDM ... the t:slim® and t:flex™ Insulin Pumps, today announced ... with Dexcom, Inc. to allow the integration of ... G5 and G6 continuous glucose monitoring ("CGM") systems. ... with Dexcom,s future CGM systems is an important ...
(Date:7/30/2015)... -- Amgen (NASDAQ: AMGN ) today announced financial ... results include: , Total revenues increased 4 ... $5,370 million, with 6 percent product sales growth ... ® (denosumab), Sensipar ® (cinacalcet), Kyprolis ... Unfavorable changes in foreign exchange rates impacted total ...
Breaking Medicine Technology:Tandem Diabetes Care Announces Development Agreement with Dexcom for Integration of Future Generation CGM Systems 2Tandem Diabetes Care Announces Development Agreement with Dexcom for Integration of Future Generation CGM Systems 3Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 2Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 3Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 4Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 5Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 6Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 7Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 8Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 9Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 10Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 11Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 12Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 13Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 14Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 15Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 16Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 17Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 18Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 19Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 20Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 21Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 22Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 23
... 8, 2012 Circassia Ltd, a specialty ... ragweed allergy therapy has achieved positive results in a ... with more severe symptoms achieved a significantly greater improvement ... on placebo (p≤0.05).  The results were presented at the ...
... 2012  InfuSystem Holdings, Inc. (NYSE Amex: INFU ... and related services, today announced that it has postponed ... 2011 results originally scheduled for March 8, 2012 in ... complete their audit.  The Company expects to announce financial ...
Cached Medicine Technology:Circassia's Ragweed Allergy Therapy Achieves Positive Phase II Clinical Results 2Circassia's Ragweed Allergy Therapy Achieves Positive Phase II Clinical Results 3InfuSystem Postpones Announcement of Fourth Quarter and Fiscal Year 2011 Earnings 2
(Date:7/31/2015)... ... July 31, 2015 , ... The 2015 New ... and family members, medical professionals, and researchers, covering a variety of topics related ... a collaborative effort between the Mesothelioma Applied Research Foundation and Memorial Sloan Kettering ...
(Date:7/31/2015)... ... July 31, 2015 , ... ... 2015”, one of the industry’s premier thought leadership symposiums, hosted by Massachusetts-based ... 6. The event attracts over 250 “C”-level executives, administrators, directors of nursing, ...
(Date:7/31/2015)... ... July 31, 2015 , ... The Mount Sinai Health System ... that evaluate the potential of related, experimental treatments. The collaboration moves into the next ... award Columbia Care one of five state licenses to produce and dispense medical marijuana. ...
(Date:7/31/2015)... ... 31, 2015 , ... Like nearly every other form of surgery, it shouldn't ... more effective and less intrusive and painful. Leading these advances in the United ... Loria currently stands as the only doctor in the United States who is qualified ...
(Date:7/31/2015)... ... July 31, 2015 , ... The Heart Fit Clinic has increased a ... a heart rate of 150 beats versus 100 beats, this is a big deal," ... to give life back to patients with heart disease," he adds. People with angina ...
Breaking Medicine News(10 mins):Health News:New York Area Mesothelioma Specialists to Present at Conference 2Health News:New York Area Mesothelioma Specialists to Present at Conference 3Health News:Harmony Healthcare International Announces Speaker Line-up for “HARMONY 2015” 2Health News:Harmony Healthcare International Announces Speaker Line-up for “HARMONY 2015” 3Health News:Mount Sinai to Collaborate with Columbia Care on Medical Marijuana Research 2Health News:Mount Sinai to Collaborate with Columbia Care on Medical Marijuana Research 3Health News:Loria Medical Penile Enlargement Center to Expand, Offering Practice Partnership to Doctors 2Health News:Heart Fit Clinic Helps Patient Increase Fitness Level with External Counterpulsation 2
... Protection Week March 1-7, 2009 FRAMINGHAM, Mass., March 2 ... the largest increase occurring at corporations and small businesses. ... that 86 percent of data breaches could be prevented, ... Protection Program ( www.identityforce.com/MPP ) in honor of National ...
... Calif., March 2 Based on its recent,analysis ... presents Veran,Medical Technologies, Inc. with the 2009 North ... the Year in recognition of its pioneering,development of ... known as,the IG4, which enables accurate and efficient ...
... System Cart Allows Easier Operation and Improved Workflow ... Traxtal Inc., the pioneer and world leader in ... newly designed system cart for the PercuNav interventional ... Booth # 322 of the Society of Interventional ...
... to new heightsHALIFAX, March 02 /PRNewswire/ - Ocean ... Omega-3 EPA/DHA food and dietary supplement ingredients from ... develop consumer awareness of the health benefits of ... awareness campaign with an interview segment ( http://www.onc.ca/Press/Docs/SEARS-WILLIAM-12.12.08.mp3 ...
... children ages 8-11 years shows contact lens wearers ... and Social Acceptance , JACKSONVILLE, Fla., March ... children beyond simply correcting their nearsightedness -- significantly ... acceptance among friends, and ability to play sports. ...
... software and services company, today announces that it has passed,the ... (TSU) 2009 label. , Misys was ... TSU service came into existence in April 2007 for its ... , The TSU, which has more ...
Cached Medicine News:Health News:New Certification Seal Identifies Merchants Committed to Fighting Identity Theft 2Health News:New Certification Seal Identifies Merchants Committed to Fighting Identity Theft 3Health News:Frost & Sullivan Lauds Veran Medical for its IG4 Plug-n-Play Navigation System 2Health News:Frost & Sullivan Lauds Veran Medical for its IG4 Plug-n-Play Navigation System 3Health News:Frost & Sullivan Lauds Veran Medical for its IG4 Plug-n-Play Navigation System 4Health News:Traxtal to Introduce Next-Generation PercuNav System Cart at SIR Annual Scientific Meeting 2Health News:Dr. William Sears and Ocean Nutrition take flight on American Airlines to Spread Consumer Awareness of the Health Benefits of Omega-3 EPA/DHA 2Health News:Dr. William Sears and Ocean Nutrition take flight on American Airlines to Spread Consumer Awareness of the Health Benefits of Omega-3 EPA/DHA 3Health News:Dr. William Sears and Ocean Nutrition take flight on American Airlines to Spread Consumer Awareness of the Health Benefits of Omega-3 EPA/DHA 4Health News:Children's Self-Perceptions Improve More With Contact Lenses vs. Glasses 2Health News:Children's Self-Perceptions Improve More With Contact Lenses vs. Glasses 3Health News:Children's Self-Perceptions Improve More With Contact Lenses vs. Glasses 4Health News:Misys Wins SWIFTReady TSU 2009 Accreditation for Third Year Running 2Health News:Misys Wins SWIFTReady TSU 2009 Accreditation for Third Year Running 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: